Sanofi to acquire Ablynx

Unanimously approved by Sanofi and Ablynx Boards of Directors

29-Jan-2018 - Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which ...

ABLYNX appoints Markus Ewert as Chief Business Officer

14-Jun-2017 - Ablynx announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company's business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for nearly 30 ...

Ablynx to receive milestone for bi-specific nanobody in oncology

01-Feb-2016 - Ablynx announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study ...

Genzyme to collaborate with Ablynx on MS research project

19-May-2015 - Ablynx announced that it has entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate Nanobodies® against a target that plays an important role in multiple sclerosis (MS) and specifically aligns with Genzyme's early-stage MS research programs involving ...

Ablynx extends ion channel research collaboration with Merck & Co.

27-Mar-2015 - Ablynx announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel.Merck & Co., Inc. will extend their ...

Ablynx's anti-vWF Nanobody achieves clinical proof-of-concept in Phase II TITAN study

First-in-class potential with orphan drug status for the treatment of acquired thrombotic thrombocytopenic purpura

18-Jun-2014 - Ablynx announced that it has achieved positive results in the Phase II TITAN study with the anti-vWF Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (TTP), a rare disorder of the blood coagulation system that causes microthrombi to form which can block small ...

Ablynx announces cancer immunotherapy discovery collaboration with Merck

04-Feb-2014 - Ablynx announced that the company has entered into a second research collaboration and licensing agreement with a subsidiary of Merck & Co., known outside the US and Canada as MSD. This new exclusive collaboration and licensing agreement is focused on the discovery and development of several ...

Ablynx and Spirogen enter in research collaboration for toxin-nanobody drug conjugates

26-Feb-2013 - Ablynx and Spirogen Ltd. announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary ...

Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies

22-Nov-2012 - Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the ...

Ablynx proposes to strengten its board

28-Sep-2012 - Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.Dr Perlmutter was Executive Vice President, Research and ...